Development of the Trevo ProVue Retriever for intracranial clot removal in acute ischemic stroke

Abstract

It is estimated that 15 million people worldwide have a stroke each year. Of the estimated 795,000 strokes that occur in the United States annually, the majority are ischemic strokes resulting from an obstruction within a vessel supplying blood to the brain. The treatment goal for these patients is to restore blood flow as quickly as possible. Increasingly, endovascular treatments that interact directly with the clot are being pursued as options. Receiving U.S. Food and Drug Administration clearance in 2012, the Trevo® Retriever is a stent-like structure to be deployed at the site of an occlusion to allow the occluding thrombus to integrate into the device for subsequent removal and restoration of blood flow. The subsequent generation of the device, the ProVue Retriever, is fully radiopaque and designed to provide physicians with maximal information about the interaction of the device with the clot, providing enhanced feedback during the procedure. In this brief historical review, the development pathway, clinical experience, and future directions of the Trevo devices are summarized.

Keywords: Trevo, retriever; clinical outcomes; ischemic stroke; thrombectomy.